Updated Sep 2, 2026
/Trump and Rubio seal Venezuela oil deal covering 65 billion barrels across 17 fields/Bond rout gathers pace as borrowing costs hit multi-decade highs/Van Jones calls El-Sayed's total Israel arms embargo 'insane,' cites Obama legacy on defense/Memecoin buys on Robinhood Wallet and Fomo coded as "digital media," sidestepping card-network crypto rules/Caring Brands (CABR) Closes $4.6 Million Initial Series B Preferred Stock Private Placement/Sanmar Group takes majority stake in AltEons Energy to back 1.5GW India pipeline/Trump and Rubio seal Venezuela oil deal covering 65 billion barrels across 17 fields/Bond rout gathers pace as borrowing costs hit multi-decade highs/Van Jones calls El-Sayed's total Israel arms embargo 'insane,' cites Obama legacy on defense/Memecoin buys on Robinhood Wallet and Fomo coded as "digital media," sidestepping card-network crypto rules/Caring Brands (CABR) Closes $4.6 Million Initial Series B Preferred Stock Private Placement/Sanmar Group takes majority stake in AltEons Energy to back 1.5GW India pipeline
NewsSOS
← NewswireMarkets

Purcell & Lefkowitz opens shareholder probe into AN2 Therapeutics directors

NEW YORK, July 20. Purcell & Lefkowitz LLP disclosed Sunday it is investigating AN2 Therapeutics, Inc. (NASDAQ: ANTX) on behalf of the company's shareholders, with the inquiry focused on whether the biotech's directors breached their fiduciary duties. The New York law firm provided no further detail on what specific conduct or corporate action prompted the probe.

By Hannah Voss2 min read
Share

Key takeaways

  • Purcell & Lefkowitz LLP disclosed on Sunday, July 20, that it is investigating AN2 Therapeutics, Inc. (NASDAQ: ANTX) on behalf of the company's shareholders.
  • The probe focuses on whether AN2 Therapeutics's directors breached their fiduciary duties.
  • The New York law firm did not identify specific board members, transactions, or decisions under review.
  • No timeline for the investigation was provided in the firm's disclosure.
  • AN2 Therapeutics trades on the Nasdaq under the ticker symbol ANTX.

NEW YORK, July 20. Purcell & Lefkowitz LLP disclosed Sunday it is investigating AN2 Therapeutics, Inc. (NASDAQ: ANTX) on behalf of the company's shareholders, with the inquiry focused on whether the biotech's directors breached their fiduciary duties. The New York law firm provided no further detail on what specific conduct or corporate action prompted the probe.

The inquiry

The investigation centers on potential fiduciary duty breaches by AN2 Therapeutics's board of directors, according to the firm's announcement. Purcell & Lefkowitz did not identify specific board members by name or disclose which transactions or decisions are under review.

No timeline for the investigation was provided in the firm's disclosure.

AN2 Therapeutics

AN2 Therapeutics is listed on the Nasdaq under the ticker symbol ANTX. The firm's announcement stated the investigation is being conducted on behalf of ANTX shareholders.

Note: The source summary is limited. This article reports only the facts disclosed. No figures, transaction details, or additional context were available in the source material.

Keep reading

All bulletins →
MarketsAugust 22, 2026

Abel leaves Berkshire Hathaway's stock picks to Buffett and portfolio manager Weschler

OMAHA, Aug. 22. Warren Buffett appears to retain control over Berkshire Hathaway's stock portfolio even after Greg Abel took over as chief executive, and portfolio manager Ted Weschler is also part of those calls. Abel, the new CEO…

2 min read
MarketsAugust 19, 2026

Nvidia starts H200 deliveries to China while Iran escalation keeps traders on watch

NEW YORK, Aug 19. Nvidia has begun shipping its H200 artificial intelligence chips to the Chinese market, the company reported, as market participants track geopolitical risks rising from an escalation in Iran

2 min read
MarketsAugust 12, 2026

OpenAI and AWS expand deal to bring Daybreak cyber models to Amazon Bedrock

SEATTLE, Aug. 12. OpenAI and Amazon Web Services have agreed to expand their partnership to include frontier cyber models, the companies said. Under the terms, OpenAI will make its Daybreak models available through the Amazon Bedrock…

2 min read

Frequently asked

Who is being investigated and by whom?

The New York law firm Purcell & Lefkowitz LLP is investigating AN2 Therapeutics, Inc. (NASDAQ: ANTX) on behalf of the company's shareholders.

What is the investigation about?

It centers on whether AN2 Therapeutics's board of directors breached their fiduciary duties.

Did the firm name specific directors or transactions?

No, Purcell & Lefkowitz did not identify specific board members by name or disclose which transactions or decisions are under review.

When was the investigation disclosed?

The firm disclosed the investigation on Sunday, July 20, from New York.

Was a timeline given for the investigation?

No timeline for the investigation was provided in the firm's disclosure.